Condition: Major Depressive Disorder · Sponsor: Intra-Cellular Therapies, Inc.
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Huntsville, Alabama, United States | Recruiting |
| CNRI-Los Angeles, LLC | Pico Rivera, California, United States | Recruiting |
| University of Connecticut Health Center | Farmington, Connecticut, United States | Recruiting |
| Vertex Clinical Research | Clermont, Florida, United States | Terminated |
| New Life Medical Research Center, Inc. | Hialeah, Florida, United States | Suspended |
| Premier Clinical Research Institute | Miami, Florida, United States | Recruiting |
| Miami Jewish Health System | Miami, Florida, United States | Recruiting |
| Interventional Psychiatry of Tampa Bay | Tampa, Florida, United States | Recruiting |
| The Emory Clinic | Atlanta, Georgia, United States | Recruiting |
| CenExeli Research LLC | Decatur, Georgia, United States | Recruiting |
| University of Kansas Medical Center Research Institute | Kansas City, Kansas, United States | Terminated |
| Collective Medical Research | Overland Park, Kansas, United States | Recruiting |
+ 57 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.